Intended Use: For Laboratory Research Use Only Key Characteristics of Retatrutide (60 mg) Triple Receptor Agonist (Research Context): Designed to engage GLP-1, GIP, and glucagon receptors in experimental systems
In total, 37 studies published through February 2025 were included, covering 9,341 participants
As many as half of all patients stop using weight management GLP-1s within 12 months.* As many as half of all patients stop using weight management GLP-1s within 12 months.* Those who are interested in trying to discontinue their medication should consult with their prescribers
Profiling the human intestinal environment under physiological conditions
Long-Lasting Effects: Regular IV sessions, complemented by proper nutrition, sustain the whitening effects over time
Keep a Short Grocery List on Your Phone Include your go-to protein, fibre, and hydration foods